|
|
 Previous Article | Table of Contents | Next Article 
A High Pretreatment Serum Vascular Endothelial Growth Factor Concentration Is Associated With Poor Outcome in Non-Hodgkin's Lymphoma
Petri Salven,
Lasse Teerenhovi, and
Heikki Joensuu
From the Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, FIN-00290 Helsinki, Finland.
Vascular endothelial growth factor (VEGF ) is a secreted endothelial cell-specific mitogen, which is induced by hypoxia and is angiogenic in vivo. Recently, elevated serum concentrations of VEGF (S-VEGF ) have been reported in patients with cancers of various histologies. However, the prognostic significance of S-VEGF in human cancer is unknown and the origin of S-VEGF remains unsettled. We measured S-VEGF by enzyme-linked immunosorbent assay from sera taken from 82 patients with non-Hodgkin's lymphoma before treatment and stored for 9 to 15 years at -20°C. All but one of the patients had been followed-up for at least 5 years or until death. S-VEGF ranged from 15 to 964 pg/mL; median, 228 pg/mL; mean, 291 pg/mL. A higher than the median S-VEGF level was associated with a poor World Health Organization performance status, a high International Prognostic Index, a high serum lactate dehydrogenase level, and a large cell histology. Patients with lower than the median S-VEGF at diagnosis had a 71% 5-year survival rate in comparison with only 49% among those with a higher than the median S-VEGF. We conclude that a high pretreatment S-VEGF level is associated with poor outcome in non-Hodgkin's lymphoma.
Blood, Vol. 90 No. 8 (July 15), 1997:
pp. 3167-3172
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. J. Robertson, B. S. Kahl, J. M. Vose, S. de Vos, M. Laughlin, P. J. Flynn, K. Rowland, J. C. Cruz, S. L. Goldberg, L. Musib, et al.
Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
May 1, 2007;
25(13):
1741 - 1746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Gratzinger, S. Zhao, R. J. Marinelli, A. V. Kapp, R. J. Tibshirani, A. S. Hammer, S. Hamilton-Dutoit, and Y. Natkunam
Microvessel Density and Expression of Vascular Endothelial Growth Factor and Its Receptors in Diffuse Large B-Cell Lymphoma Subtypes
Am. J. Pathol.,
April 1, 2007;
170(4):
1362 - 1369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos and D. Morgensztern
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
995 - 1007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Keller, A. V. Schally, K. Groot, G. L. Toller, A. Havt, F. Koster, P. Armatis, G. Halmos, M. Zarandi, J. L. Varga, et al.
Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone
PNAS,
July 26, 2005;
102(30):
10628 - 10633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes, B. Pro, M. J. Robertson, I. W. Flinn, J. E. Romaguera, F. Hagemeister, N. H. Dang, P. Fiumara, E. M. Loyer, F. F. Cabanillas, et al.
Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma and Hodgkin's Disease
Clin. Cancer Res.,
August 15, 2004;
10(16):
5432 - 5438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bono, A. Krause, M. von Mehren, M. C. Heinrich, C. D. Blanke, S. Dimitrijevic, G. D. Demetri, and H. Joensuu
Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib
Blood,
April 15, 2004;
103(8):
2929 - 2935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T.-P. Poon, C. P.-Y. Lau, S.-T. Cheung, W.-C. Yu, and S.-T. Fan
Quantitative Correlation of Serum Levels and Tumor Expression of Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma
Cancer Res.,
June 15, 2003;
63(12):
3121 - 3126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. F. Dvorak
Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy
J. Clin. Oncol.,
November 1, 2002;
20(21):
4368 - 4380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hayashibara, Y. Yamada, T. Miyanishi, H. Mori, T. Joh, T. Maeda, N. Mori, T. Maita, S. Kamihira, and M. Tomonaga
Vascular Endothelial Growth Factor and Cellular Chemotaxis: A Possible Autocrine Pathway in Adult T-Cell Leukemia Cell Invasion
Clin. Cancer Res.,
September 1, 2001;
7(9):
2719 - 2726.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Wong, M. Alfert, D. H. Castrillon, Q. Shen, J. Holash, G. D. Yancopoulos, and L. Chin
Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome
PNAS,
June 7, 2001;
(2001)
121192298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Niemelä, H. Mäenpää, P. Salven, P. Summanen, K. Poussa, L. Laatikainen, J. Jääskeläinen, and H. Joensuu
Interferon {{alpha}}-2a Therapy in 18 Hemangioblastomas
Clin. Cancer Res.,
March 1, 2001;
7(3):
510 - 516.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
J. Clin. Oncol.,
February 15, 2001;
19(4):
1207 - 1225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold
Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival
J. Clin. Oncol.,
January 15, 2001;
19(2):
577 - 583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Braybrooke, K. J. O’Byrne, D. J. Propper, A. Blann, M. Saunders, N. Dobbs, C. Han, J. Woodhull, K. Mitchell, J. Crew, et al.
A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis
Clin. Cancer Res.,
December 1, 2000;
6(12):
4697 - 4704.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu
Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients
Blood,
December 1, 2000;
96(12):
3712 - 3718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aguayo, H. Kantarjian, T. Manshouri, C. Gidel, E. Estey, D. Thomas, C. Koller, Z. Estrov, S. O'Brien, M. Keating, et al.
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Blood,
September 15, 2000;
96(6):
2240 - 2245.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Aguayo, S. O'Brien, M. Keating, T. Manshouri, C. Gidel, B. Barlogie, M. Beran, C. Koller, H. Kantarjian, and M. Albitar
Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia
Blood,
July 15, 2000;
96(2):
768 - 770.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bertolini, L. Fusetti, P. Mancuso, A. Gobbi, C. Corsini, P. F. Ferrucci, G. Martinelli, and G. Pruneri
Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma
Blood,
July 1, 2000;
96(1):
282 - 287.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Federico, U. Vitolo, P. L. Zinzani, T. Chisesi, V. Clo, G. Bellesi, M. Magagnoli, M. Liberati, C. Boccomini, P. Niscola, et al.
Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases
Blood,
February 1, 2000;
95(3):
783 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kuramoto, T. Uesaka, A. Kimura, M. Kobayashi, H. Watanabe, and O. Katoh
ZK7, a Novel Zinc Finger Gene, Is Induced by Vascular Endothelial Growth Factor and Inhibits Apoptotic Death in Hematopoietic Cells
Cancer Res.,
January 1, 2000;
60(2):
425 - 430.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Salven, L. Teerenhovi, and H. Joensuu
A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin's Lymphoma
Blood,
November 15, 1999;
94(10):
3334 - 3339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Hefler, C. Tempfer, A. Obermair, K. Frischmuth, G. Sliutz, A. Reinthaller, S. Leodolter, and C. Kainz
Serum Concentrations of Vascular Endothelial Growth Factor in Vulvar Cancer
Clin. Cancer Res.,
October 1, 1999;
5(10):
2806 - 2809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Salven, A. Orpana, and H. Joensuu
Leukocytes and Platelets of Patients with Cancer Contain High Levels of Vascular Endothelial Growth Factor
Clin. Cancer Res.,
March 1, 1999;
5(3):
487 - 491.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Wong, M. Alfert, D. H. Castrillon, Q. Shen, J. Holash, G. D. Yancopoulos, and L. Chin
Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome
PNAS,
June 19, 2001;
98(13):
7481 - 7486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
